肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
4期
290-293
,共4页
王春霞%吕红丽%朱慎梅%张凤琴%尚翠娟
王春霞%呂紅麗%硃慎梅%張鳳琴%尚翠娟
왕춘하%려홍려%주신매%장봉금%상취연
宫颈癌%奈达铂%顺铂%临床疗效%安全性
宮頸癌%奈達鉑%順鉑%臨床療效%安全性
궁경암%내체박%순박%림상료효%안전성
Cervical carcinoma%Nedaplatin%Cisplatin%Clinical efficacy%Safety
目的:比较奈达铂和顺铂同步放化疗治疗晚期宫颈癌的临床疗效及安全性。方法选择2011年1月~2013年3月我院收治的70例晚期宫颈癌患者,并将其随机分为观察组(奈达铂同步放化疗)和对照组(顺铂同步放化疗),每组35例。化疗4周后,观察和比较两组的客观有效率、疾病控制率、CD3+、CD4+、NK细胞的百分率及不良反应的发生情况。结果化疗前,两组患者免疫功能指标的差异无统计学意义(P>0.05);化疗后,观察组的客观有效率、疾病控制率以及CD3+、CD4+、NK细胞的百分率均显著高于对照组,不良反应的发生率显著低于对照组(P<0.05)。结论奈达铂同步放化疗较顺铂同步放化疗治疗晚期宫颈癌更加有效,且安全性更好,具有更高的临床应用价值。
目的:比較奈達鉑和順鉑同步放化療治療晚期宮頸癌的臨床療效及安全性。方法選擇2011年1月~2013年3月我院收治的70例晚期宮頸癌患者,併將其隨機分為觀察組(奈達鉑同步放化療)和對照組(順鉑同步放化療),每組35例。化療4週後,觀察和比較兩組的客觀有效率、疾病控製率、CD3+、CD4+、NK細胞的百分率及不良反應的髮生情況。結果化療前,兩組患者免疫功能指標的差異無統計學意義(P>0.05);化療後,觀察組的客觀有效率、疾病控製率以及CD3+、CD4+、NK細胞的百分率均顯著高于對照組,不良反應的髮生率顯著低于對照組(P<0.05)。結論奈達鉑同步放化療較順鉑同步放化療治療晚期宮頸癌更加有效,且安全性更好,具有更高的臨床應用價值。
목적:비교내체박화순박동보방화료치료만기궁경암적림상료효급안전성。방법선택2011년1월~2013년3월아원수치적70례만기궁경암환자,병장기수궤분위관찰조(내체박동보방화료)화대조조(순박동보방화료),매조35례。화료4주후,관찰화비교량조적객관유효솔、질병공제솔、CD3+、CD4+、NK세포적백분솔급불량반응적발생정황。결과화료전,량조환자면역공능지표적차이무통계학의의(P>0.05);화료후,관찰조적객관유효솔、질병공제솔이급CD3+、CD4+、NK세포적백분솔균현저고우대조조,불량반응적발생솔현저저우대조조(P<0.05)。결론내체박동보방화료교순박동보방화료치료만기궁경암경가유효,차안전성경호,구유경고적림상응용개치。
Objective To compare the clinical efficacy between nedaplatin and cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical carcinoma. Methods A total of 70 patients with advanced cervical cancer admitted in our hospital between January 2011 and March 2013 were enrolled in this study, and were randomly divided into observation group and control group, 35 cases in each group. Patients in the observation group were given nedaplatin concurrent chemo-radiotherapy, and those in the control group were given cisplatin concurrent chemoradiotherapy. After 4 weeks of chemo-therapy, the objective response rate, disease control rate, cellular immunological function and incidence of adverse reactions were observed and compared between the two groups. Results Before chemotherapy, the difference of immune function in-dex had no statistical significance (P>0.05). After chemotherapy, the objective response rate, disease control rate, and per-centages of CD3+, CD4+, NK cells of the observation group were significantly higher than those of the control group (P<0.05). In addition, the adverse reactions incidences of the observation group were lower than those of the control group (P<0.05). Conclusion The nedaplatin concurrent chemoradiotherapy had better clinical efficacy than of cisplatin concurrent chemo-radiotherapy in the treatment of advanced cervical carcinoma. It had better safety and higher clinical significance.